Summit Global Investments Has $4.81 Million Stock Position in HCA Healthcare, Inc. (NYSE:HCA)

Summit Global Investments lifted its stake in HCA Healthcare, Inc. (NYSE:HCA) by 387.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,026 shares of the company’s stock after acquiring an additional 12,739 shares during the period. Summit Global Investments’ holdings in HCA Healthcare were worth $4,810,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of HCA. FMR LLC grew its stake in shares of HCA Healthcare by 322.3% in the third quarter. FMR LLC now owns 3,141,769 shares of the company’s stock worth $1,276,909,000 after acquiring an additional 2,397,883 shares during the last quarter. Royal London Asset Management Ltd. boosted its stake in HCA Healthcare by 62.0% during the fourth quarter. Royal London Asset Management Ltd. now owns 1,500,786 shares of the company’s stock worth $450,461,000 after buying an additional 574,239 shares in the last quarter. Principal Financial Group Inc. boosted its stake in HCA Healthcare by 120.1% during the fourth quarter. Principal Financial Group Inc. now owns 873,775 shares of the company’s stock worth $262,264,000 after buying an additional 476,756 shares in the last quarter. Meritage Group LP acquired a new stake in HCA Healthcare during the third quarter worth $150,548,000. Finally, Raymond James Financial Inc. acquired a new stake in HCA Healthcare during the fourth quarter worth $74,121,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

Shares of NYSE:HCA opened at $329.25 on Friday. The stock has a market capitalization of $81.06 billion, a P/E ratio of 14.99, a P/E/G ratio of 1.10 and a beta of 1.68. HCA Healthcare, Inc. has a 1-year low of $289.98 and a 1-year high of $417.14. The business has a 50-day moving average price of $321.50 and a two-hundred day moving average price of $343.43. The company has a current ratio of 1.08, a quick ratio of 0.97 and a debt-to-equity ratio of 69.07.

HCA Healthcare (NYSE:HCA) last posted its earnings results on Friday, January 24th. The company reported $6.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.03 by $0.19. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. During the same quarter last year, the company posted $5.90 earnings per share. Equities analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 17th will be given a $0.72 dividend. The ex-dividend date of this dividend is Monday, March 17th. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.66. This represents a $2.88 annualized dividend and a dividend yield of 0.87%. HCA Healthcare’s payout ratio is currently 13.11%.

Insider Activity at HCA Healthcare

In related news, SVP Jennifer Berres sold 9,533 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $322.59, for a total value of $3,075,250.47. Following the completion of the transaction, the senior vice president now directly owns 15,412 shares in the company, valued at approximately $4,971,757.08. The trade was a 38.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

HCA has been the topic of several recent analyst reports. Raymond James downgraded shares of HCA Healthcare from an “outperform” rating to a “market perform” rating in a research note on Friday, November 22nd. Morgan Stanley reduced their target price on shares of HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Barclays reduced their target price on shares of HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 price target on shares of HCA Healthcare in a report on Monday, January 27th. Finally, KeyCorp cut their price target on HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating for the company in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, HCA Healthcare presently has a consensus rating of “Moderate Buy” and a consensus target price of $385.67.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.